Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults

Heart

Volumn 101, Issue 17, 2015, Pages 1368-1374

  Macheret, Fima ^a   Bartz, Traci M ^b   Djousse, Luc ^c   Ix, Joachim H ^d   Mukamal, Kenneth J ^e   Zieman, Susan J ^f   Siscovick, David S ^g   Tracy, Russell P ^h   Heckbert, Susan R ⁱ   Psaty, Bruce M ⁱ   Kizer, Jorge R ^j  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g NEW YORK ACADEMY OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE 1 76; ANTIHYPERTENSIVE AGENT; ESTROGEN; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HEART LEFT ATRIUM; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; WEIGHT REDUCTION; AGING; BLOOD; CLINICAL TRIAL; INCIDENCE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; UNITED STATES; UPREGULATION; VERY ELDERLY;

ADIPONECTIN; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ATRIAL FIBRILLATION; BIOMARKERS; FEMALE; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84941638318     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-307015     Document Type: Article

References (30)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
2. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
3. Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009;120:1768-74.
4. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
5. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008;117:1255-60.
6. Karmazyn M, Purdham DM, Rajapurohitam V, et al. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008;79:279-86.
7. Kizer JR, Benkeser D, Arnold AM, et al. Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the cardiovascular health study. Circulation 2012;126:2951-61.
8. Kizer JR, Benkeser D, Arnold AM, et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab 2013;98:255-63.
9. Karas MG, Benkeser D, Arnold AM, et al. Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults =65 years of age (from the Cardiovascular Health study). Am J Cardiol 2014;113:328-34.
10. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163:119-24 e1.
11. Knuiman M, Briffa T, Divitini M, et al. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol 2014;29:181-90.
12. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995;5:270-7.
13. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-76.
14. Cushman M, Cornell ES, Howard PR, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264-70.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
16. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-18.
17. De Filippi CR, De Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
18. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009;119:606-18.
19. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005;11:1096-103.
20. Kizer JR. Adiponectin, cardiovascular disease, and mortality: Parsing the dual prognostic implications of a complex adipokine. Metabolism 2014;63:1079-83.
21. Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010;121:200-7.
22. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7.
23. Ouchi N, Walsh K. A novel role for adiponectin in the regulation of inflammation. Arterioscler Thromb Vasc Biol 2008;28:1219-21.
24. Kizer JR, Arnold AM, Strotmeyer ES, et al. Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality. The Cardiovascular Health Study All Stars Study. J Gerontol A Biol Sci Med Sci 2010;65:1208-14.
25. Van Berendoncks AM, Garnier A, Beckers P, et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010;3:185-94.
26. Takano H, Obata JE, Kodama Y, et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 2009;132:221-6.
27. Skurk C, Wittchen F, Suckau L, et al. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 2008;29:1168-80.
28. Khan RS, Kato TS, Chokshi A, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail 2012;5:340-8.
29. Dastani Z, Hivert MF, Timpson N, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45, 891 individuals. PLoS Genet 2012;8:e1002607.
30. Kizer JR. A tangled threesome: adiponectin, insulin sensitivity, and adiposity: can Mendelian randomization sort out causality? Diabetes 2013;62:1007-9.